Market Performance - The three major A-share indices collectively rebounded today, with the Shanghai Composite Index rising by 0.63% to close at 3863 points, the Shenzhen Component Index increasing by 0.98%, and the ChiNext Index up by 1.98% [1] - The total market turnover was 1.75 trillion yuan, a decrease of 203.1 billion yuan compared to the previous trading day, with over 4000 stocks rising [1] Sector Performance - The cultivated diamond sector saw explosive growth, with stocks like Huanghe Xuanfeng, Sifangda, and Hengsheng Energy hitting the daily limit [1] - The coal sector experienced significant gains, with stocks such as Baotailong, Zhengzhou Coal Electricity, and Baotai Group also reaching the daily limit [1] - Gas stocks rose, with Guo Xin Energy hitting the daily limit [1] - The CPO concept was active, with Cambridge Technology hitting the daily limit [1] - Other sectors with notable gains included F5G concept, robotics, digital watermarking, and brain-computer interface [1] - Conversely, precious metals and gold concepts saw significant declines, with Hunan Silver and Western Gold hitting the daily limit down [1] - The jewelry sector declined, with Cuihua Jewelry dropping over 8% [1] - The rare earth permanent magnet sector weakened, led by Xinlaifu [1] - Other sectors with notable declines included small metals, genetically modified products, and pork and chicken concepts [1] Index Performance - Shanghai Composite Index: 3863.89 (+24.14, +0.63%) [1] - Shenzhen Component Index: 12813.21 (+124.27, +0.98%) [1] - ChiNext Index: 2993.45 (+58.09, +1.98%) [1] - Other indices such as the Sci-Tech 50, CSI 300, and CSI 500 also showed positive movements [1]

创新药板块涨幅靠前，睿智医药20cm涨停，海南海药、联化科技、哈三联、华森制药等多股10cm涨停。消息面上，5 月29日，国家药品监督管理局批准了11款创新药物上市，相关研发成果涉及多个新药研发技术领域，覆盖了肿瘤、自 身免疫性疾病、代谢等多个治疗领域。其中，多款药品为相关领域"国内首款"或"国产首款"。 | 代码 | 名称 | 涨幅量 | 涨跌 | 现价 | | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | +19.98% | +1.71 | 10.27 | | 688131 | 皓元医药 | +15.26% | +5.84 | 44.10 | | 300204 | 計泰神 | +15.02% | +3.46 | 26.50 | | 430047 | 诺思兰德 | +14.87% | +2.71 | 20.94 | | 688799 | 华纳药厂 | +12.94% | +5.31 | 46.36 | | 688488 | 艾迪药业 | +11.96% | +1.48 | 13.85 | | 000266 | 海南海药 | +10.07% | +0.56 | ...

Market Overview - The A-share market experienced an overall decline on May 30, with most major indices falling, although the declines were generally modest [2][6] - The Hong Kong market also saw a drop, with the Hang Seng Index falling over 1% [6] Innovation Drug Sector - The innovation drug concept surged, with the sector showing an overall increase of approximately 3%, leading to a wave of stocks hitting the daily limit up [2] - Notable stocks in the innovation drug sector included Ruizhi Pharmaceutical, which hit a limit up of 20cm, and Warner Pharmaceuticals, both seeing significant gains [2][3] - The sector's performance is supported by recent research indicating that the number of Chinese innovative drugs selected for the 2025 ASCO summary has reached a new high, reflecting a leap in R&D competitiveness and increasing international influence [4] Specific Company Performances - In the Hong Kong market, CSPC Pharmaceutical Group saw its stock price surge by over 12% following the announcement of potential licensing and cooperation deals, with total potential payments from these deals estimated to reach around $5 billion [6] - Li Auto reported a total vehicle delivery of 92,864 units in Q1 2025, marking a year-on-year increase of 15.5%, with total revenue reaching RMB 25.9 billion, a slight increase from the previous year [7] - Li Auto's net profit for Q1 2025 was RMB 646.6 million, up 9.4% year-on-year, although it represented a significant decrease from the previous quarter [8]